MNTA: If there is only one generic Lovenox approved what are the factors that Sanofi-Aventis will look at in determining whether to launch an authorized generic? What is the downside in Sanofi-Aventis' perspective in launching an authorized generic if only one generic Lovenox is approved by the FDA? I have read on various boards that a generic could capture up to 80% of the Lovenox market. Why wouldn't Sanofit automatically launch an authorized generic if that is likely to happen?
Market Data 
Markets 
AI
